Shopping Cart
Remove All
Your shopping cart is currently empty
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor that suppresses KIF18A microtubule-dependent ATPase activity with an IC50 of 0.016 μM. It reduces HCC15 tumour volume in mouse models and may be employed in KIF18A-associated cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $66 | - | In Stock | |
| 5 mg | $158 | - | In Stock | |
| 10 mg | $257 | - | In Stock | |
| 25 mg | $438 | - | In Stock | |
| 50 mg | $579 | - | In Stock | |
| 100 mg | $809 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $197 | - | In Stock |
| Description | KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor that suppresses KIF18A microtubule-dependent ATPase activity with an IC50 of 0.016 μM. It reduces HCC15 tumour volume in mouse models and may be employed in KIF18A-associated cancer research. |
| Targets&IC50 | KIF18A microtubule-dependent ATPase activity:0.016 μM |
| In vitro | KIF18A-IN-6 demonstrates inhibitory effects on the viability of JIMT-1, HCC-15, and NIH-OVCAR3 cells, with corresponding IC50 values of 0.0040, 0.0051, and 0.0051 μM, respectively. [1] |
| In vivo | KIF18A-IN-6 (10-60 mg/kg, once or twice daily for 1 month) administered orally effectively inhibited the growth of HCC15 and OVCAR3 tumors in mice. [1] |
| Molecular Weight | 559.74 |
| Formula | C28H37N3O5S2 |
| Cas No. | 2914879-10-8 |
| Smiles | O=C(C1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C)N2C3=CC=C(C=C3C4(C2)CCC5(CC4)CC5)NS(=O)(=O)CC |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (178.65 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (5.9 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.